PETV.US PetVivo Holdings Inc
- Market cap
- USD 19.5M
- P/E
- -
- P/B
- 14.46x
- ROE
- -
- Dividend yield
- 2.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is PETV.US undervalued?
Graham numberThe Graham number of PetVivo Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PetVivo Holdings Inc fundamental analysis
No fundamental analysis for PetVivo Holdings Inc yet.
PetVivo Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. The company is based in Edina, Minne…
Full company profilePetVivo Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PetVivo Holdings Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.12K | 1.51K | 77.9K | 3.59K | 12.6K | 116K | 917K | 969K | 1.13M | 1.14M | 1.10M |
| Gross Profit | 7.12K | -642K | -77.9K | -16.1K | 1.88K | -85.6K | 390K | 740K | 995K | 755K | 839K |
| Operating Income | -16.4M | -2.29M | -4.67M | -2.02M | -1.96M | -5.06M | -8.73M | -10.6M | -8.06M | -8.06M | -7.05M |
| EBITDA | - | -1.64M | -3.92M | -1.49M | -1.87M | -4.99M | -8.62M | -10.5M | -7.69M | -8.86M | -6.74M |
| Net Income | -15.5M | -2.34M | -4.76M | -2.11M | -3.75M | -4.94M | -8.70M | -11.0M | -8.40M | -10.5M | -7.12M |
| EPS | -7.41 | -0.61 | -1.03 | -0.39 | -0.61 | -0.56 | -0.85 | -0.78 | -0.41 | -0.35 | -0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 1.90M | 1.57M | 691K | 523K | 835K | 7.43M | 2.44M | 3.12M | 9.34M | 3.58M | 2.15M |
| Total Liabilities | 1.08M | 1.43M | 1.54M | 1.56M | 1.73M | 1.44M | 1.71M | 2.43M | 5.12M | 1.38M | 2.31M |
| Shareholders' Equity | 820K | 137K | -845K | -1.04M | -897K | 5.99M | 725K | 686K | 4.22M | 2.20M | -159K |
| Cash & Short-term Investments | 25.4K | 237K | 6.46K | 2.39K | 23.6K | 6.11M | 475K | 87.4K | 378K | 351K | 16.3K |
| Total Debt | - | 193K | 105K | 537K | 733K | 333K | 345K | 1.37M | 2.90M | 376K | 1.40M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -143K | -579K | -736K | -497K | -1.05M | -4.17M | -6.79M | -7.42M | -5.32M | -6.11M | -3.83M |
| Capital Expenditure | 19.2K | 52.7K | 106K | 76.2K | 160K | 183K | 424K | 309K | 563K | 7.73K | 49.5K |
| Free Cash Flow | - | -632K | -842K | -573K | -1.21M | -4.36M | -7.22M | -7.73M | -5.89M | -6.12M | -3.83M |
| Ratios | |||||||||||
| ROE | -1,894.7% | -1,710.5% | - | - | - | -82.5% | -1,200.2% | -1,597.1% | -199.1% | -476.2% | - |
| ROA | -818.8% | -149.1% | -688.4% | -404.8% | -449.1% | -66.5% | -356.8% | -351.7% | -89.9% | -292.8% | -331.8% |
| Net Profit Margin | -218,017.0% | -154,790.6% | -6,104.7% | -58,944.2% | -29,824.9% | -4,275.4% | -948.8% | -1,130.9% | -741.6% | -917.4% | -646.9% |
| Debt to Equity | - | 1.41x | - | - | - | 0.06x | 0.48x | 1.99x | 0.69x | 0.17x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PetVivo Holdings Inc dividends
- Dividend yield
- 2.07%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 404K | 0.01 | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 30.0K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:4 on Dec 30, 2020.
Who owns PetVivo Holdings Inc
- Insiders 55.28%
- Institutions 0.00%
- Public & others 44.72%
- Shares outstanding 38.0M
- Free float 26.4M
Top funds holding PETV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SSgA U.S. Extended Market Index Class I | 2.30K | 0.01% | 0.00% | Dec 2023 |
Top institutions holding PETV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ridgewood Investments LLC | 0.00 | 0.00% | -100.00% | Sep 2024 |
PetVivo Holdings Inc company profile
- Company name
- PetVivo Holdings Inc
- Ticker
- PETV.US
- Exchange
- USA Stocks
- Listed since
- May 23, 2013
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 22
- Fiscal year end
- March
- Address
- 5151 Edina Industrial Boulevard, Edina, MN, United States, 55439
- Phone
- 952 405 6216
- Website
- petvivo.com
About PetVivo Holdings Inc
PetVivo Holdings, Inc., a biomedical device company, manufactures, commercializes, and licenses medical devices and therapeutics for animals in the United States. The company's lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. It also provides therapeutic devices for veterinary and human clinical applications. The company is based in Edina, Minnesota.
PetVivo Holdings Inc management
6- Mr. John LaiCEO, President & Director · born 1962
- Mr. Garry N. LowenthalChief Financial Officer · born 1959
- Mr. John F. DolanGeneral Counsel, Chief Business Development Officer & Secretary · born 1965
- Mr. Bryan MonningerVice President of Sales & Distributor Relations
- Ms. Andrea CranstonVice President of Marketing
- Dr. Juli Goldstein D.V.M.Technical Service Veterinarian